{"id":18342,"date":"2025-09-16T21:37:35","date_gmt":"2025-09-16T16:07:35","guid":{"rendered":"http:\/\/43.205.138.160\/?post_type=article&p=18342"},"modified":"2025-09-16T21:37:35","modified_gmt":"2025-09-16T16:07:35","slug":"daily-chart-analysis-of-sunpharma","status":"publish","type":"article","link":"https:\/\/signalz.pro\/article\/daily-chart-analysis-of-sunpharma\/","title":{"rendered":"Daily Chart Analysis of SUNPHARMA"},"content":{"rendered":"

Technical Chart Analysis \u2013 Sun Pharma (Daily)
\n<\/u><\/strong>Sun Pharma is currently trading around \u20b91610<\/strong>, showing signs of stabilization after a corrective decline. On the daily chart, the stock has recently rebounded from the \u20b91580 support zone<\/strong>, where buyers stepped in to defend the level.<\/p>\n

Moving Averages (MAs):<\/strong> The stock is trading below its short-term and medium-term moving averages (20, 50, and 100 DMA), which are currently acting as resistance in the \u20b91630\u20131650 zone<\/strong>. A breakout and sustained close above these averages will confirm strength and may open the door for further upside toward \u20b91685\u20131720 levels<\/strong>. On the downside, the 200 DMA near \u20b91550<\/strong> is a strong support level.<\/p>\n

Parabolic SAR:<\/strong> Dots are still above the price, signaling that the short-term trend is yet to fully reverse<\/strong> into a confirmed bullish trend. A few more positive candles may flip the SAR below the price, indicating buying momentum.<\/p>\n

RSI (Relative Strength Index):<\/strong> RSI is at 49<\/strong>, hovering around the neutral zone, which shows neither overbought nor oversold conditions. This means the stock is at a make-or-break zone<\/strong>, where the next move could set the short-term direction.<\/p>\n

MACD (Moving Average Convergence Divergence):<\/strong> The MACD line is below the signal line but flattening, suggesting that downside momentum is slowing. If crossover happens in the coming sessions, it will generate a bullish momentum signal<\/strong>.<\/p>\n

Summary View
\nSupport Levels:<\/strong> \u20b91580 \u2013 \u20b91550
\nResistance Levels:<\/strong> \u20b91630 \u2013 \u20b91650 (immediate), \u20b91685 \u2013 \u20b91720 (next)
\nTrend Outlook:<\/strong> Stock is in consolidation with a bias shifting towards recovery. Sustaining above \u20b91650 will attract fresh buying interest.<\/p>\n

Sun Pharma \u2013 Detailed Analysis
\n<\/u>1. Micro View (Company Specific)
\nTechnical Setup:<\/strong> Stock is consolidating near \u20b91600 with support at \u20b91550 and resistance around \u20b91650\u20131685. Momentum indicators suggest a possible rebound if volumes increase.
\nFundamentals:<\/strong> Sun Pharma remains India\u2019s largest pharma company with strong leadership in chronic therapies, dermatology, and specialty drugs in the US market. Its robust pipeline of specialty products and acquisitions in emerging markets support long-term growth.
\nRecent Performance:<\/strong> Q1 FY26 results showed steady revenue growth, led by US specialty business and domestic formulations. Margins improved slightly due to cost efficiency measures.<\/p>\n

    \n
  1. Macro View (Sector & Economy)
    \nSector Trends:<\/strong> Indian pharma sector is benefiting from increasing healthcare demand, patent expiries in the US, and a rising focus on generics + specialty products.
    \nGlobal Outlook:<\/strong> With the US FDA approvals becoming more frequent and demand for low-cost generics rising, Indian pharma companies like Sun Pharma are well-positioned.
    \nRisks:<\/strong> Pricing pressure in US generics, regulatory hurdles, and currency fluctuations may impact near-term performance.<\/li>\n<\/ol>\n

    3.Upcoming Events & Possible Impact
    \nUSFDA Inspections\/Approvals:<\/strong> Any new approval for specialty products in dermatology or oncology will likely boost sentiment and stock price.
    \nQuarterly Results (Q2 FY26):<\/strong> If Sun Pharma continues its growth momentum in the US + Indian markets, the stock could see a strong re-rating.
    \nBudget \/ Policy Announcements:<\/strong> Government\u2019s push on healthcare spending and incentives for domestic manufacturing (PLI schemes) may provide long-term tailwinds.
    \nGlobal Events:<\/strong> Any major shift in US pharma pricing policy or patent wins\/losses could directly impact earnings visibility.<\/p>\n

    Investment View
    \nShort Term (1\u20133 months):<\/strong> Consolidation likely in \u20b91550\u20131650 range; breakout above \u20b91650 may target \u20b91685\u20131720.
    \nMedium Term (3\u20136 months):<\/strong> Stable outlook with growth driven by US specialty products; price target zone \u20b91750\u20131820.
    \nLong Term (1+ year):<\/strong> Strong structural story; leadership in pharma, R&D pipeline, and global expansion may take the stock above \u20b92000+.<\/p>\n

    Disclaimer
    \n<\/strong>This analysis is prepared for educational and informational purposes only. It should not be considered as investment advice or a buy\/sell recommendation. Stock market investments are subject to risks. Please consult your financial advisor before making any investment decisions.<\/p>\n

    Disclosure
    \n<\/strong>We, at Investogainer Research, are a SEBI Registered Research Analyst (INH000012856) and also listed with BSE (Code: 5845). We do not hold any personal or family positions in this stock. Our views are unbiased and based on technical and fundamental research.<\/p>\n","protected":false},"template":"","article-category":[35],"article-tags":[386,400,130,163,183,133,92,128,116,162,168,127],"class_list":["post-18342","article","type-article","status-publish","hentry","article-category-learn","article-tags-optionstrading","article-tags-technicalanalysis","article-tags-expert-analysis","article-tags-financialeducation","article-tags-investingtips","article-tags-investment-strategies","article-tags-sebi-registered-advisors","article-tags-sebi-registered-analysts","article-tags-signalzinvestmenttips","article-tags-stockmarket","article-tags-stockmarkettips","article-tags-successful-investing"],"acf":[],"_links":{"self":[{"href":"https:\/\/signalz.pro\/api\/wp\/v2\/article\/18342","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/signalz.pro\/api\/wp\/v2\/article"}],"about":[{"href":"https:\/\/signalz.pro\/api\/wp\/v2\/types\/article"}],"wp:attachment":[{"href":"https:\/\/signalz.pro\/api\/wp\/v2\/media?parent=18342"}],"wp:term":[{"taxonomy":"article-category","embeddable":true,"href":"https:\/\/signalz.pro\/api\/wp\/v2\/article-category?post=18342"},{"taxonomy":"article-tags","embeddable":true,"href":"https:\/\/signalz.pro\/api\/wp\/v2\/article-tags?post=18342"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}